Spotlight On... Investors applaud Schein's record sales and earnings; MWI picks up St. Francis Group; Nexvet misses estimates; Sanofi's Merial charts modest growth; and more...

Shares of distributor Henry Schein ($HSIC) were up more than 6% to $156.91 in morning trading on February 10, after the company announced record fourth-quarter and full-year results. Schein's net sales for the quarter were up 5% year over year to $2.9 billion, while its adjusted net income grew 7% to $139.3 million ($1.67 per share). Sales in the company's animal health division rose 3% to $756.2 million. For the full year, Schein chalked up sales of $10.6 billion, up 2.5% from 2014, and adjusted net income of $501.5 million or $5.96 per share, which was almost a 10% improvement from the previous year. CEO Stanley Bergman noted in the earnings release that he expects Schein to get a further boost from its recent acquisitions of health analytics company Vetstreet and practice-management software maker RxWorks. Release

> AmerisourceBergen's ($ABC) MWI Animal Health acquired the U.K.'s St. Francis Group, an animal health buying company, for an undisclosed sum. Release

> Nexvet ($NVET) reported a net loss of $5.7 million (49 cents) in its second fiscal quarter, missing the average analyst estimate by two cents. Release

> Sanofi ($SNY) reported that its animal health unit, Merial, reported fourth-quarter sales growth of 5.9% year-over-year on a constant-currency basis to €559 million ($628.3 million) and 2015 growth of 10.8% to €2.5 billion ($2.8 billion). Release (PDF)

> Jaguar Animal Health ($JAGX) announced that it has closed its offering of 2 million shares, with net proceeds of $4.6 million. Release

> ImmuCell ($ICCC) announced that sales in the fourth quarter rose 22% year-over-year to $2.7 million and net income came in at $289,000, or 9 cents a share, while the company charted full-year sales growth of 35% to $10.2 million and earnings of 1.2 million (38 cents a share). Release

> Kindred Biosciences ($KIN) announced it has filed the effectiveness section of its New Animal Drug Application (NADA) to the FDA for Zimeta (previously KIN-012) to treat pyrexia in horses. Release

> A new chain of 13 vet hospitals called Ethos Veterinary Health has been formed via the merger of IVG Hospitals of New England, Premier Veterinary Group of Chicago, Wheat Ridge Animal Hospital of Denver and Veterinary Specialty Hospital of San Diego. Release

> SQI Diagnostics, which develops assays for pharma and animal health researchers, announced that sales in its first fiscal quarter were up more than 12-fold year-over-year to $197,000 but that the net loss was flat at $1.4 million (2 cents a share). Release

> Merck ($MRK) Animal Health has launched Pet Diabetes Tracker, a free app for pet owners managing diabetes in their dogs or cats. Release

> IDEXX Laboratories ($IDXX) announced the retirement of Johnny Powers, executive vice president of its companion animal unit. Release

> Ireland-based drug manufacturer Chanelle Group, which produces medicines for the human and veterinary markets, announced it has invested €70 million ($78.1 million) to expand its production capacity and research and development activities. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…